VelosBio: Merck Snaps Up VelosBio and its ROR1 Inhibitor in $2.75 Billion Deal

Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.